WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
– Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – – Commenced startup for a Phase 2 clinical trial in COPD; on track for first patient to be dosed in H2...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.9 | -15.1041666667 | 19.2 | 20.168 | 15.6731 | 202945 | 17.68182034 | CS |
4 | -6.53 | -28.6027157249 | 22.83 | 24.975 | 14.97 | 496194 | 17.91910006 | CS |
12 | -5.2 | -24.1860465116 | 21.5 | 29.35 | 14.97 | 372777 | 21.17104912 | CS |
26 | -5.2 | -24.1860465116 | 21.5 | 29.35 | 14.97 | 372777 | 21.17104912 | CS |
52 | -5.2 | -24.1860465116 | 21.5 | 29.35 | 14.97 | 372777 | 21.17104912 | CS |
156 | -5.2 | -24.1860465116 | 21.5 | 29.35 | 14.97 | 372777 | 21.17104912 | CS |
260 | -5.2 | -24.1860465116 | 21.5 | 29.35 | 14.97 | 372777 | 21.17104912 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約